Influence of Dietary Supplementation for Hyperhomocysteinemia Treatments

• Main Authors: Alessandra Vezzoli, Cinzia Dellanoce, Teresa Maria Caimi, Daniele Vietti, Michela Montorsi, Simona Mrakic-Sposta, Roberto Accinni
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Nutrients
• Subjects: magnesium oxoprolinate; folic acid; thiols; homocysteine; randomized study
• Online Access: https://www.mdpi.com/2072-6643/12/7/1957
• ISSN: 2072-6643

Hyperhomocysteinemia is recognized as risk factor for cardiovascular and age-associated diseases. Folic acid supplementation efficiently lowers plasma homocysteine (Hcy) levels, but high intake may negatively affect health because of unnatural levels of unmetabolized folic acid in the systemic circulation. Oxoproline (Oxo) provides by glutamic acid production an increase of intracellular folic acid trapping. Aim of this study was to compare the efficacy of three supplementation protocols: (1) traditional therapy (5-methyl-tetrahydrofolate: 15 mg/day); (2) 5 mL/day of Oxo with 300 μg folic acid (oxifolic); (3) 5 mL/day of Oxo alone (magnesio+) in a 90 days randomized trial on thirty-two moderate hyperhomocysteinemic (18.6 ± 2.4 μmol.L⁻¹) patients (age 48 ± 14 yrs). Thiols: cysteine (Cys), cysteinylglycine (Cys–Gly) and glutathione levels were assessed too. Every supplementation induced significant (<i>p</i> range <0.05–0.0001) reductions of Hcy level and Cys concentration after the three protocols adopted. Otherwise glutathione concentration significantly increased after oxifolic (<i>p </i><<i> </i>0.01) and traditional (<i>p </i><<i> </i>0.05) supplementation. The integration of Oxo resulted an interesting alternative to traditional therapy because absence or minimal number of folates in the integrator eliminates any chance of excess that can constitute a long-term risk.